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Abstract
Background: Resistant ovary syndrome (ROS) is a rare endocrine disorder characterized with hypergonadotrophic
hypogonadism. Infertility is a common complaint of woman presenting with ROS, and little progress has been
made in term of reproduction with the patient’s own gamete. So far only one case report of live birth has been
reported after in vitro maturation (IVM) of oocytes in a patient suffering from ROS in 2013.
Case presentation: A secondary infertile woman of 33 years-old was manifested with oligomenorrhea and markedly
increased gonadotropin levels around postmenopausal range, but had normal antral follicle count, normal serum
inhibin B and anti-Müllerian hormone levels. She had normal karyotype of 46,XX and normal thyroid function. There
were no abnormal findings in some autoantibody assays and FSH receptor sequencing. After oral contraceptive pills
combined with triptorelin depot were administered, her gonadotropin levels reduced but it showed no response
to high doses of exogenous gonadotropins (hp-HMG 300IU/d for 15 days). Then endometrium was prepared
with estradiol valerate and IVM from small antral follicles were performed. Five immature oocytes were retrieved.
Twenty-four hours after IVM culture, 3 oocytes matured to metaphase II stage and were inseminated by
intracytoplasmic sperm injection using her husband’s sperm. Two top-quality embryos were transferred
and one embryo was cryopreserved. The patient got pregnant and delivered a healthy boy at term.
Conclusion: IVM using their own oocytes could be an available treatment for infertile women with ROS.
Keywords: Resistant ovary syndrome, In vitro maturation of oocytes, Infertility
Abbreviations: AMH, Anti-Müllerian hormone; E2, Estradiol; GV, Germinal vesicle; hCG, Human chorionic gonadotropin;
ICSI, Intracytoplasmic sperm injection; IUD, Intrauterine device; IVM, In vitro maturation; PCR, Polymerase chain reaction;
POI, Primary ovarian insufficiency; PRL, Prolactin; ROS, Resistant ovary syndrome; T, Testosterone
Background
Resistant ovary syndrome (ROS) is a rare endocrine
disorder characterized with hypergonadotrophic hypo-
gonadism, which was first described in 1969 [1]. Inferti-
lity is a common complaint of woman presenting with
ROS at reproductive age, and indeed treatment is a great
challenge for both clinicians and patients. Little progress
has been made in term of reproduction with the patient’s
own gamete. Several researchers have reported successful
return of menstruation after ovarian biopsy, normalization
of ovarian function and subsequent spontaneous preg-
nancy after hormone replacement therapy in very few
cases [2, 3]. Patients with ROS usually have to accept egg
donation because ovarian follicles were unresponsive to
endogenous or exogenous FSH [4].
With the breakthrough in assisted reproductive tech-
nique, in vitro maturation (IVM) of oocytes has emerged
as a reliable option in the management of infertility, and
even been expanded in some uncommon situations [5].
To the best of our knowledge, so far only one case report
of live birth has been reported after IVM of oocytes in a
29-years old patient suffering from ROS in 2013 [6]. The
case we now presented here was the second one. However,
we had ever tried to use IVM to treat a patient of ROS as
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early as in 2005, available oocytes and embryos were
successfully obtained but regrettably the patient was not
pregnant after embryo transfer. Here we shared this case
report aiming to provide further evidence to support the
effectiveness of IVM in ROS patients.
Case presentation
Patient history
In August 2014, a 33-year-old multiparous woman with
an 8-years history of secondary infertility was referred to
our IVF center. She had got married for 10 years and
gave a normal child birth in 2005. After delivery she
used intrauterine device (IUD) for contraception and
IUD was released one year later. But she failed to con-
ceive ever since. In 2008, hysterosalpingography showed
bilateral salpingitis with bilateral hydrosalpinx and PPD
tuberculin test was strong positive. Diagnosed doubtfully
as pelvic tuberculosis in local hospital, then she received
anti tuberculosis treatment for one year. In 2013, hyste-
roscopy revealed normal uterine cavity, and proliferative
endometrium was confirmed by histopathology examin-
ation. Her menarche occurred at 16 years old and she had
regular menses previously. Since 2008, she suffered from
oligomenorrhea or amenorrhea with the cycle length of
40 to 90 days. She denied any endocrine or autoimmune
disorders. She had a normal body mass index and did not
present any clinical androgen excess signs. She was occa-
sionally given oral contraceptive pills to induce menses.
The study was approved by the ethics committee of
Sun Yat-sen Memorial Hospital of Sun Yat-sen University.
Informed consent has been obtained.
Hormonal measurements and ultrasound scans
Initial hormone measurements and ultrasound scans were
checked on day 3 of a spontaneous menstruation. Serum
levels of FSH, LH, E2, prolactin and total testosterone
were determined using an automated multianalysis system
with chemiluminescence detection (UniCel Dxi 800 Acess,
Beckman Coulter, USA). Serum AMH level was deter-
mined using ELISA (Ansh Labs, England). Serum inhibin
B level was determined using a double antibody ELISA
(Serotec). Ultrasound scans were performed using a
5.0- to 8.0-MHz multifrequency transvaginal probe
(GE Voluson E8) by one single operator.
Initial hormonal profile demonstrated FSH and LH
levels were around the menopausal range. While AMH
and inhibin B levels were normal, and ultrasound scan
showed normal size of uterus and ovaries with total 25
antral follicles of 2mm to 7mm in diameter. The patient
was given by hormone replacement therapy (Femonton;
Abbott Biologicals B.V., the Netherlands) to induce regu-
lar withdrawal bleeding for 3 months and during the time
serial ultrasonic monitoring displayed no evidence of
dominant follicular growth. Repeated hormonal evaluation
on day 3 after withdrawal bleeding still showed high FSH
and LH level. The hormonal and ultrasonographic profiles
were described in details in Table 1 and Fig. 1.
Conventional chromosome analysis and FSH receptor
sequencing
The patient’s karyotype showed normal 46,XX. Sanger se-
quencing identified 4 variants in the FSHR gene: c.-29G >
A, c.299 + 33C > T, c.919G > A (p.Ala307Thr) and c.2039
G > A (p.Ser680Asn). All of the 4 variants were identified
Table 1 Hormonal and Ultrasonographic Profiles
Initial measurement Repeated measurements Intra-assay CV (%) Inter-assay CV (%) Functional sensitivity
FSH (IU/l) 41.99 38.18 /42.41 4.30 / 0.20
LH (IU/l) 39.29 36.27 /46.21 5.40 / 0.20
E2 (pmol/l) 260.57 202.11/248.36 15.00 / 73.40
AMH (ng/ml) 12.27 / ≤10 ≤15 0.06
Inhibin B (pg/ml) 40.59 / ≤10 ≤15 10
Antral follicle count 25 20/24 / / /
T(nmol/l) 1.24 / 3.93 7.08 0.35
PRL (mIU/L) 188.68 / 1.42 / 5.30
TSH(mIU/L) 1.79 / 2.30 1.40 0.005
FT4(pmol/L) 16.72 / 2.23 4.00 1.30
FT3(pmol/L) 4.61 / 2.35 / 0.30
Anti-TPO(IU/mL) <28.0 / 6.80 3.40 28.0
Anti-TG(IU/mL) <15.0 / 6.30 7.00 25.0
CV coefficients of variation, TSH thyroid stimulating hormone, T4 total thyroxine, FT4 free thyroxine, T3 total triiodothyronine, FT3 free triiodothyronine, Anti-TPO
thyroid peroxidase antibody, Anti-TG thyroglobulin antibody
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benign variants by the use of SIFT (http://sift.jcvi.org/)
and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/)
and searching the databases, the Human Gene Mutation
database (http://www.hgmd.org/), the dbSNP (http://www.
ncbi.nlm.nih.gov/snp). The details were shown in Fig. 2.
Thyroid function and some autoantibody assays
Serum levels of thyroid function including thyroid stimulat-
ing hormone, total thyroxin, free thyroxin, total triiodothy-
ronine, free triiodothyronine, thyroid peroxidase antibody
and thyroglobulin antibody were determined using chemi-
luminescence detection (Siemens Healthcare Diagnostics
Inc, USA). Serum antiovarian antibody was determined
using ELISA (Shenzhen anquan Biotech Co., Ltd, China).
Serum antizona pellucida antibody was determined using
ELISA (Weifang kanghua Biotech Co., Ltd, China). There
were no abnormal findings in thyroid function and these
autoantibodies.
Ovarian stimulation and IVM procedure
Twenty-one consecutive days of oral contraceptive
pills (Marvelon; Organon Pharmaceutical Co Ltd, The
Netherlands) were prescribed to the patient. On the 15th
day of oral contraceptive pills, serum hormone concentra-
tions dropped down: FSH 3.03 IU/L, LH 3.88 IU/L and E2
73.40pmol/L, then a single dose of 1.25 mg triptorelin
depot (Decapeptyl 3.75mg; Ferring Pharmaceuticals Ltd,
The Netherlands) was administrated for pituitary down-
regulation. After 14 days of triptorelin injection, which
was on the sixth day of withdrawal bleeding, endogenous
Fig. 1 Transvaginal ultrasound scans of two ovaries with normal number of antral follicles, in line with normal AMH levels but in contrast with
high serum FSH and LH
Fig. 2 Partial sequencing results of genetic variations in the patient for the FSHR gene. a Forward sequences in the patient. The arrow indicates the
heterozygous variation c.-29G > A of 5′-UTR. b Forward sequences in the patient. The arrow indicates the heterozygous variation c.299 + 33C > T
of intron 3. c Forward sequences in the patient. The arrow indicates the heterozygous variation c.919G > A (p.Ala307Thr) of exon 10. d Forward
sequences in the patient. The arrow indicates the heterozygous variation c.2039G > A (p.Ser680Asn) of exon 10
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gonadotropin dropped to FSH 1.35 IU/L, LH 3.22 IU/L
and E2 104.14pmol/L. Then we started ovarian stimula-
tion. Firstly, 100IU/d recombinant FSH beta (Puregon;
Organon Pharmaceutical Co Ltd, The Netherlands) com-
bined with 75IU/d highly purified menotrophin (Hp-hMG)
(Menopur; Ferring Pharmaceuticals Ltd, The Netherlands)
were administrated for 4 days. Ultrasound scan showed that
no follicle developed larger than 5 mm in diameter and the
thickness of endometrium was less than 4mm, as well
serum E2 level was still low, 91.75 pmol/l. Then gonado-
tropin was changed to 300IU/d Hp-hMG for another 11
days, but it still showed that only small antral follicles, thin
endometrium and unchanged serum E2 level. Considering
the patient was unresponsive to endogenous and exogenous
gonadotropin, we decided to try IVM procedures after a
fully consultation with the couple. On following 7 days,
4mg/d estradiol valerate (Progynova; Bayer Schering
Pharma, France) was given orally for endometrial prepar-
ation. Finally after 15-days ovarian stimulation and 7-days
oral estradiol valerate, endometrial thickness reached to 8.0
mm and small follicles were still 2 to 5 mm in diameter.
Then 10 000 IU human chorionic gonadotropin (hCG)
(Lizhu Pharmaceutical Co, China) was administrated.
About 36 h after hCG administration. 5 immature oocytes
were retrieved by ultrasound guidance with 17G single-
lumen aspiration needle (Cook; William Cook Australia
Pty Ltd, Australia) under a reduced aspiration pressure
of 10.7 kPa.
IVM procedure
IVM medium (SAGE In-Vitro Fertilization, Inc. USA) at
the concentration of 0.075IU/mL was prepared by 10 ml
stock solution added with 100 ul Hp-hMG(Menopur;
Ferring Pharmaceuticals Ltd, The Netherlands). Oocyte-
cumulus complexes were matured in 1 ml IVM medium
for 24 h, afterwards oocytes were denuded of cumulus
cells and checked for maturity. Three out of five oocytes
reached metaphase II stage and were inseminated by
intracytoplasmic sperm injection (ICSI) using the partner’s
spermatozoa, whereas two oocytes were still immature on
germinal vesicle (GV) stage. After ICSI, three oocytes were
normally fertilized and embryo evaluation and selection
was performed 68 h after ICSI.
Embryo transfer and follow-up
On day three after ICSI, three embryos were obtained and
two top quality embryos with eight cells and <5 % fragmen-
tation were transferred into the uterus, while one embryo
was cryopreserved. Luteal support with 40 mg/day natural
progesterone in oil (Lizhu Pharmaceutical Co, China) and
oral administration of 20 mg/day dydrogesterone (Abbott
Biologicals B.V., the Netherlands) were started on the day
of ICSI, in combination with continuous estradiol valerate
treatment. Fourteen days after embryo transfer, serum
ß-hCG was positive and luteal support continued until 10
gestational-weeks. The pregnancy evolved without com-
plications and she uneventfully delivered a healthy boy,
3200 g, at term.
Discussions
Resistant ovary syndrome, previously known as Savage
Syndrome, is a rare disease of unknown etiology. So far
there are only a few reports described in the literature.
The manifestations of ROS involve primary or secondary
amenorrhea, normal secondary sexual characters, an
age-compatible number of small antral follicles, normal
chromosome, elevated gonadotropin levels of menopausal
range, and unresponsiveness to gonadotropin stimulation.
ROS might be misdiagnosed as primary ovarian insuffi-
ciency (POI). The main difference between ROS and POI
is the presence of a normal amount of antral follicles in
ROS, while few or no follicles are found in POI. In the
past ovarian biopsy has been required to clarify a diagnosis
of ROS, but nowadays many non-invasive approaches are
helpful in proving the presence of antral follicles. It is well
known that antral follicles as small as 2 mm in diameter
can be visualized by high-resolution transvaginal ultraso-
nography [7]. Furthermore, hormone biomarkers such as
inhibin B and AMH have been suggested to have a diag-
nostic role in women with ROS [4, 7], which are secreted
by granulosa cells of growing follicles and closely related
to ovarian reserve. In the report of Arici et al, Inhibin B
has a diagnostic role in two women with ROS who mani-
fested by secondary amenorrhea, high gonadotropin level
but normal inhibin B level and normal primordial follicles
after ovarian biopsy, while AMH level was not measured
[4]. However, in the report of Grynberg et al, the case with
ROS showed very low inhibin B level but normal AMH
level [6]. The case in this report showed normal both
inhibin B and AMH level. The conflicting results could be
explained by the existence of different sizes of antral folli-
cles in the ovary among different women with ROS. The
intrafollicular concentrations of AMH become progres-
sively lower with increasing follicle diameters but concen-
trations of inhibin B increased with increasing follicle
diameter in human small antral follicles [8]. Thereafter
AMH could be a better biomarker than inhibin B for
discriminating ROS and POI, due to it correlates with ova-
rian primordial follicle number even after adjustment for
chronological age [9]. According to the clinical manifesta-
tions and biomarkers, the patient in this report should be
diagnosed as ROS.
ROS has long been an enigma. Mueller et al [3] reported
there was no indication for any autoimmune disease
in a patient with ROS and tests for antinuclear antibodies,
antiphospholipid antibodies, lupus anticoagulant and anti-
cardiolipin antibodies were all negative. Arici et al [4]
also found no autoantibodies against thyroid, adrenals, or
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ovaries in two women with ROS. Grynberg et al [6] con-
ducted more detailed genetic and autoimmune explorations
in a 29-year-old patient, including karyotype, sequencing of
FSH and LH receptor genes, analysis of GDF9, FOXL2,
BMP15 genes and FRAXA mutation, as well as adrenal
cortex autoantibodies, steroid cell autoantibodies, serum
21-hydroxylase, 17-hydroxylase and P450 side-chain clea-
vage enzyme autoantibodies, yet revealed no abnormality.
Similarly, our case showed no history of autoimmune
diseases, normal karyotype, no deleterious mutations in
FSHR gene, and some negative autoantibodies. Gonado-
tropin receptor or hormone mutations were rarely found
in sporadic cases of gonadotropin resistance [10, 11].
While ROS showed few links with genetics, since family
history, chromosome and gonadotropin receptor as well
as post-receptor defects analysis invariably proved to be
normal [6, 12, 13]. Thereafter, gonadotropin resistance in
ROS women might be due to defects in interactions of
FSH and its receptor, mostly secondary to autoimmune
activities [14, 15]. Some reports demonstrated that antigo-
nadotropin antibodies were found in women with gonado-
tropin resistance [13, 16, 17]. ROS could be another
special condition of reproductive autoimmune failure that
has been described elsewhere [18, 19]. The patient in
this report had a medical history of pelvic tuberculosis
and oligomenorrhea or amenorrhea occurred after anti-
tuberculosis therapy. While mycobacterial tuberculosis
infections are known to induce the development of auto-
antibodies and even autoimmune diseases [20, 21]. In a
recent study of ROS case, it demonstrated that IgG/IgM-
antibodies directed against some forms of gonadotropins
were found in serum and respective antibodies in this
serum only react with some but not all forms of FSH [13].
And the expressed fashion of FSHR, LHR as well as estro-
gen receptor beta and progesterone receptor A induced
by exogenous gonadotropins was not different in granu-
losa cells from ROS patient and from control patients
[13]. But the ROS case in this report showed normal
response to ovarian stimulation with daily 75IU recombi-
nant beta and 225IU hp-HMG for 14 days after hormone
replacement and GnRH agonist treatment. 11 mature
oocytes were obtained and a successful live birth after
embryo transfer [13]. Several common autoantibodies
associated with infertility were not detected in our ROS
case but it is limited that antigonadotropin antibodies have
not been tested. It need be further investigated whether the
possible mechanism of autoimmunity can explain gonado-
tropin resistance in all ROS patients, and the titers or types
of antigonadotropin antibodies are related to that ovarian
response has or not and which kind of exogenous gonado-
tropin should be effective.
Infertility is a difficult issue for ROS patients at repro-
ductive age, and the chances of fertility with their own
oocytes are unpredictable and most likely poor. Attempts
to stimulate follicle development with high doses of
gonadotropins to override the resistant state seem to be
invalid [3, 4, 6]. Indeed we tried to induce follicle growth
with 300IU daily hp-HMG for 15 days, but no response.
Taking into consideration the first pregnancy and live
birth after IVM in ROS case was reported in 2013 [6], we
tried the same method. Three out of five oocytes were
matured in vitro, and the transfer of two top-quality
embryos resulted in a successful live birth. These two
successful cases with ROS by IVM also confirm that granu-
losa cells can response to exogenous gonadotropin in vitro
and IVM overcomes the state of gonadotropin resistance in
ROS patients. Finally, no choice but IVF using donor
oocytes was the only option for ROS in case of IVM and all
other treatment failures [4], undoubtedly the reproductive
prognosis was acceptable in the donor oocyte program.
Conclusion
The ROS patient can obtain available oocytes/embryos
and live birth by IVM even after she shows no response
to ovarian stimulation with large dose of exogenous
gonadotropin. IVM should be an option available for
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